Evidence map›Paper›PMID 32060643›Full record

ArticleJournal of cancer research and clinical oncology2020

A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level.

Qi Liu, Kuanyu Wang, Ruoyu Huang, Xuezhi Tong, Tao Jiang, Jiangfei Wang, Pei Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qi LiuDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Kuanyu WangGamma Knife Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Ruoyu HuangDepartment of Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Xuezhi TongDepartment of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Tao JiangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jiangfei WangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. wjf1998@sohu.com.
Pei YangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. peiyang87@163.com.ORCID http://orcid.org/0000-0003-0102-6272

Funding

Beijing Tiantan Miaopu Project No. 2017MP05National Key Research and Development Plan No.2016YFC0902500National Natural Science Foundation of China No. 81903060
6 · The paper itself

Abstract

purposeThe WHO classification for IDH-mutant grade II and grade III astrocytoma may not be as prognostically meaningful as expected. We aimed to develop a novel classification system based on the DNA damage response signature.

methodsWe developed the gene signature of DNA damage response with 115 samples from The Cancer Genome Atlas (TCGA) database. The dataset from Chinese Glioma Genome Atlas (CGGA) database with 41 samples was used as the validation set. Lasso Cox regression model was applied for selection of the best signature. Gene set enrichment analysis (GSEA) and gene ontology (GO) analysis were implemented to reveal its biological phenotype.

resultsA two-gene DNA damage response signature (RAD18, MSH2) was developed using the lasso Cox regression model based on the TCGA dataset. Its prognostic efficiency was validated in the CGGA cohort. The result of Cox regression analysis showed that the signature has a better predictive accuracy than the WHO grade. The risk score was an independent prognostic factor for the overall survival of the IDH-mutant grade II and grade III astrocytoma. GSEA and GO analysis confirmed enhanced processes related to DNA damage response in high-risk group.

conclusionWe developed a two-gene signature which can effectively predict the prognosis of patients with IDH-mutant grade II and grade III astrocytoma. It suggests a novel classification of astrocytoma with better prognostic accuracy based on the expression of DNA damage response genes.

Indexed as

TranscriptomeAdultAstrocytomaDNA DamageFemaleHumansIsocitrate DehydrogenaseMaleMiddle AgedPrognosisIsocitrate DehydrogenaseAstrocytomaDNA damage responseGene signaturePrognosis

Identifiers

PMID32060643
PMCPMC11804327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.